Navigation Links
Michael J. Fox Foundation Announces $2 Million Funding Commitment to Drive Development of Parkinson's Disease Biomarker Pipeline

Initiative is one element of broader strategy to speed biomarkers progress

NEW YORK, May 7 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research announced a funding commitment of $2 million for Biomarkers 2009. This fourth round of biomarker funding by MJFF aims to continue stimulating discovery of new disease and drug biomarkers. At the same time, recognizing the critical need for an orchestrated, fieldwide strategy to drive tangible progress, MJFF is putting building blocks in place to launch a comprehensive biomarker discovery and verification effort in coming months.

"Lack of biomarkers is a major impediment to the development of disease-modifying treatments for Parkinson's disease, in large part because outcomes of clinical trials are extremely difficult to measure," said Katie Hood, CEO. "While considered a high-risk pursuit by many, The Michael J. Fox Foundation will continue to push biomarker research because development of PD biomarkers would be a major tipping point for the field, greatly accelerating the development of transformative new therapies."

The Foundation has been a field leader in the development of PD biomarkers for several years. Approximately $9 million in MJFF investment to date has resulted in the emergence of several lead biomarker candidates. Today's additional $2 million, directed toward biomarker discovery, underscores that commitment. Biomarkers 2009 will prioritize continued development of two separate types of biomarkers, both of major importance to PD therapeutics development: disease biomarkers and drug biomarkers.

Disease biomarkers are distinctive biological features or changes that are consistently different in people with PD than in people without PD. Identifying one or more disease biomarkers would allow researchers to diagnose earlier, track disease progression and identify appropriate subjects for clinical trials. Drug biomarkers are critical for objectively assessing whether a given drug is reaching brain areas of interest and/or achieving a desired effect.

Abbreviated information for applicants is below. Full details are available at

Biomarkers 2009

Total available funding: $2 million

Deadline: 6 p.m. ET, Thursday, August 13, 2009

Funding Anticipated: November/December 2009

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded over $142 million in research to date.

    Media Contact:
    Holly Barkhymer
    (212) 509-0995 x242

    Research Contact:
    Mark Frasier, PhD
    (212) 509-0995 x244

SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Celebrated Architect Michael Graves to Keynote HEALTHCARE DESIGN.09 Conference
2. Aleres Dr. Michael Taitel Provides Insights Into Reducing Health and Productivity Costs During Turbulent Economic Times
3. Dr. Michael B. Cates Takes Leadership Role on AVMAs One Health Joint Steering Committee
4. NeuroFocus Appoints Dr. Michael Smith as Partner in Consulting Practice
5. Sigma-Aldrich Announces Appointment of Michael Kanan as Vice President and Corporate Controller
6. J. Michael Cook to Retire from Lilly Board of Directors
7. Michael J. Kussman, VA Under Secretary for Health, to Retire
8. Foundation for Biomedical Research Announces Michael E. DeBakey Journalism Awards
9. Michael DeMane Joins Thomas, McNerney & Partners as Senior Advisor
10. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
11. HealthWorldWeb Adds Michael Millenson and J.D. Kleinke to Board of Advisors
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Mohebi Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 West ... in innovative solutions for injectable drug administration, today announced ... the market opens on Thursday, October 26, 2017, and ... results and business expectations at 9:00 a.m. Eastern Time. ... or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
Breaking Medicine Technology: